Abubaker. M. E. Sidahmed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abubaker. M. E. Sidahmed has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Arpit Sharma
Immunogenetics and Transplant Immunology Laboratory University Hospital, London Health Sciences Centre London Ontario Canada
6 shared publicationsDavid Beaune
Immunogenetics and Transplant Immunology Laboratory University Hospital, London Health Sciences Centre London Ontario Canada
6 shared publicationsSabina Al Agbar
Department of Pathology and Laboratory Medicine, London Health Science Centre
6 shared publicationsA. Sharma
Immunogenetics and Transplantation Laboratory, London Health Sciences Centre and Pathology and Laboratory Medicine University Hospital London Ontario Canada
4 shared publicationsD. Beaune
Immunogenetics and Transplantation Laboratory, London Health Sciences Centre and Pathology and Laboratory Medicine University Hospital London Ontario Canada
4 shared publications- Lakshman Gunaratnam
Division of Nephrology University Hospital London Ontario Canada
4 shared publications
Latest Publications
Characterisation of the HLA‐DPA1*01:194:01:02 Allele by Next‐Generation Sequencing
Novel HLA‐DPA1*01:194:01:02 allele identified in Canadian liver transplant candidate of European descent by next‐generation sequencing.
Characterisation of the HLA‐DPA1*01:194:01:02 Allele by Next‐Generation Sequencing
Novel HLA‐DPA1*01:194:01:02 allele identified in Canadian liver transplant candidate of European descent by next‐generation sequencing.
- Open Access
- 15 July 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1832945
Understanding the role of non-HLA antibodies in kidney transplantation: a literature review
Non-HLA antibodies have emerged as important contributors to antibody-mediated rejection and long-term graft dysfunction in kidney transplantation, including in patients without detectable donor-specific antibodies against human leukocyte antigens (HLA-DSAs). This review summarizes current evidence on major non-HLA antibody targets, including angiotensin II type 1 receptor, endothelin A receptor, perlecan fragment LG3, vimentin, major histocompatibility complex class I chain-related molecule A, collagen, fibronectin, natural antibodies, and glutathione S-transferase theta 1, and highlights their mechanisms of formation, pathogenic roles, and clinical associations. These antibodies can arise through alloimmune or autoimmune processes, often driven by endothelial injury, ischemia-reperfusion injury, and inflammatory signaling, which may expose cryptic antigens and promote loss of self-tolerance. Mechanistically, non-HLA antibodies can mediate graft injury through complement activation, Fc receptor–dependent immune responses, and direct signaling effects on endothelial and vascular cells, leading to inflammation, microvascular injury, and fibrosis. Importantly, they can act synergistically with HLA-DSA, amplifying immune responses, and contributing to worse transplant outcomes. However, findings across studies remain inconsistent due to heterogeneity in detection methods, lack of standardized thresholds for positivity, and variability in patient populations. Additionally, temporal dynamics in antibody development and fluctuations over time suggest that static measurements may not fully capture their clinical relevance. The presence of non-HLA antibodies in healthy populations further complicates interpretation and highlights the need to better define clinically meaningful thresholds. Given the wide diversity in antigen targets, biological functions, and mechanisms of action, a one-size-fits-all approach is insufficient. Instead, individual non-HLA antibodies should be investigated through targeted mechanistic and clinical studies to clarify their specific roles in transplant outcomes. Future research should prioritize large-scale, multicenter prospective studies with standardized methodologies, alongside mechanistic investigations, to improve risk stratification and advance understanding of their impact on long-term kidney transplant success.
- 15 July 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1832945
Open AccessUnderstanding the role of non-HLA antibodies in kidney transplantation: a literature review
Non-HLA antibodies have emerged as important contributors to antibody-mediated rejection and long-term graft dysfunction in kidney transplantation, including in patients without detectable donor-specific antibodies against human leukocyte antigens (HLA-DSAs). This review summarizes current evidence on major non-HLA antibody targets, including angiotensin II type 1 receptor, endothelin A receptor, perlecan fragment LG3, vimentin, major histocompatibility complex class I chain-related molecule A, collagen, fibronectin, natural antibodies, and glutathione S-transferase theta 1, and highlights their mechanisms of formation, pathogenic roles, and clinical associations. These antibodies can arise through alloimmune or autoimmune processes, often driven by endothelial injury, ischemia-reperfusion injury, and inflammatory signaling, which may expose cryptic antigens and promote loss of self-tolerance. Mechanistically, non-HLA antibodies can mediate graft injury through complement activation, Fc receptor–dependent immune responses, and direct signaling effects on endothelial and vascular cells, leading to inflammation, microvascular injury, and fibrosis. Importantly, they can act synergistically with HLA-DSA, amplifying immune responses, and contributing to worse transplant outcomes. However, findings across studies remain inconsistent due to heterogeneity in detection methods, lack of standardized thresholds for positivity, and variability in patient populations. Additionally, temporal dynamics in antibody development and fluctuations over time suggest that static measurements may not fully capture their clinical relevance. The presence of non-HLA antibodies in healthy populations further complicates interpretation and highlights the need to better define clinically meaningful thresholds. Given the wide diversity in antigen targets, biological functions, and mechanisms of action, a one-size-fits-all approach is insufficient. Instead, individual non-HLA antibodies should be investigated through targeted mechanistic and clinical studies to clarify their specific roles in transplant outcomes. Future research should prioritize large-scale, multicenter prospective studies with standardized methodologies, alongside mechanistic investigations, to improve risk stratification and advance understanding of their impact on long-term kidney transplant success.
The Novel HLA‐C*01:303 Allele, Identified in a Living Liver Donor of Canadian Dutch Descendent
The novel HLA‐C*01:303 allele was identified in a Canadian donor of Dutch descent by next‐generation sequencing.
The Novel HLA‐C*01:303 Allele, Identified in a Living Liver Donor of Canadian Dutch Descendent
The novel HLA‐C*01:303 allele was identified in a Canadian donor of Dutch descent by next‐generation sequencing.
The Novel DPB1*1927:01N Allele, Identified in a Potential Kidney Donor
HLA‐DPB1*1927:01N differs from HLA‐DPB1*15:01:01:01 by a single base substitution in exon 3 .
The Novel DPB1*1927:01N Allele, Identified in a Potential Kidney Donor
HLA‐DPB1*1927:01N differs from HLA‐DPB1*15:01:01:01 by a single base substitution in exon 3 .
- Open Access
- 23 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1690461
Positive B cell flow cytometry crossmatch without detectable donor-specific antibodies: true or false reactivity?
In kidney transplant workups, supplementing flow cytometry crossmatches (FCXMs) with solid-phase assays (SPAs) helps differentiate between true positive from false positive results, which can prevent unnecessary waitlist delays. This study presents an analysis of three discordant cases characterized by positive B-cell FCXM results and the absence of detectable donor-specific antibodies (DSAs). Peripheral blood samples were obtained from both recipients and donors for HLA typing, FCXM, antibody screening, and surrogate crossmatches, with expanded single antigen bead assays at One Lambda laboratory to detect unidentifiable antibodies. Initial FCXM positivity did not correlate with SPA-confirmed DSAs. However, surrogate crossmatch results varied: Recipient 1 had unacceptable antigen leading to a halted transplant, Recipient 2’s negative results allowed the transplant to proceed, and Recipient 3’s mixed results led to the decision not to proceed with the transplant due to an unacceptable antigen. The findings suggest that a positive FCXM, in the absence DSAs, may be interpreted as false positive, underscoring the necessity for comprehensive testing in the pre-transplant evaluation process. Employing multiple diagnostic techniques ensures more accurate risk assessments, improves transplant outcomes, and expands the pool of suitable donors, emphasizing the critical role of thorough HLA and non-HLA antibody evaluations.
- 23 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1690461
Open AccessPositive B cell flow cytometry crossmatch without detectable donor-specific antibodies: true or false reactivity?
In kidney transplant workups, supplementing flow cytometry crossmatches (FCXMs) with solid-phase assays (SPAs) helps differentiate between true positive from false positive results, which can prevent unnecessary waitlist delays. This study presents an analysis of three discordant cases characterized by positive B-cell FCXM results and the absence of detectable donor-specific antibodies (DSAs). Peripheral blood samples were obtained from both recipients and donors for HLA typing, FCXM, antibody screening, and surrogate crossmatches, with expanded single antigen bead assays at One Lambda laboratory to detect unidentifiable antibodies. Initial FCXM positivity did not correlate with SPA-confirmed DSAs. However, surrogate crossmatch results varied: Recipient 1 had unacceptable antigen leading to a halted transplant, Recipient 2’s negative results allowed the transplant to proceed, and Recipient 3’s mixed results led to the decision not to proceed with the transplant due to an unacceptable antigen. The findings suggest that a positive FCXM, in the absence DSAs, may be interpreted as false positive, underscoring the necessity for comprehensive testing in the pre-transplant evaluation process. Employing multiple diagnostic techniques ensures more accurate risk assessments, improves transplant outcomes, and expands the pool of suitable donors, emphasizing the critical role of thorough HLA and non-HLA antibody evaluations.
First Report of the HLA‐DQB1*03:575 Allele in a Kidney Transplant Recipient of European Descent
The new HLA‐DQB1*03:575 differs from HLA‐DQB1* 03:03:02:01 by a single base substitution at exon 2.
First Report of the HLA‐DQB1*03:575 Allele in a Kidney Transplant Recipient of European Descent
The new HLA‐DQB1*03:575 differs from HLA‐DQB1* 03:03:02:01 by a single base substitution at exon 2.
Identification of the HLA‐B*27:277 Allele in Individuals of European Descent and Native American Descent
HLA‐B*27:277 differs from HLA‐B*27:05:02:05 by a single substitution in exon 6.
Identification of the HLA‐B*27:277 Allele in Individuals of European Descent and Native American Descent
HLA‐B*27:277 differs from HLA‐B*27:05:02:05 by a single substitution in exon 6.
The newly characterised HLA‐B*41:84 allele, found in a prospective liver transplant candidate
HLA‐B*41:84 has a single base substitution in exon 2, altering glutamic acid to glutamine’.
The newly characterised HLA‐B*41:84 allele, found in a prospective liver transplant candidate
HLA‐B*41:84 has a single base substitution in exon 2, altering glutamic acid to glutamine’.
The novel HLA‐DQA1*05:05:17:03 allele, identified in a potential organ donor
HLA‐DQA1*05:05:17:03 differs from HLA‐DQA1*05:05:01:02 by a single base substitution in exon 1 and HLA‐DQA1*05:05:17:01 within introns 1 and 2.
The novel HLA‐DQA1*05:05:17:03 allele, identified in a potential organ donor
HLA‐DQA1*05:05:17:03 differs from HLA‐DQA1*05:05:01:02 by a single base substitution in exon 1 and HLA‐DQA1*05:05:17:01 within introns 1 and 2.
The novel HLA‐C*06:372 allele, identified in a stem cell donor of an old order mennonite ethnicity
HLA‐C*06:372 differs from HLA‐C*06:02:01:01 by a single substitution in exon 4.
The novel HLA‐C*06:372 allele, identified in a stem cell donor of an old order mennonite ethnicity
HLA‐C*06:372 differs from HLA‐C*06:02:01:01 by a single substitution in exon 4.